Rankia España
Acceder

pamogu

Rankiano desde hace más de 6 años
54
Publicaciones
28
Recomendaciones
--
Seguidores
Posición en Rankia
Posición último año
Resumen
Respuestas 54
Recomendados 13
Guardados 3
11/04/16 15:24
Ha respondido al tema Farmas USA
Sí, entonces es como comentas. Pagarías la prima (ahora mismo entre 0,70 y 1,05) por tener la oportunidad de comprarlas a 10$ al vencimiento.
Ir a respuesta
11/04/16 12:59
Ha respondido al tema Farmas USA
Comprar una opcion por vender es una Put. En este caso pagarías 4,90 - 5,60
Ir a respuesta
16/12/15 13:35
Ha respondido al tema Farmas USA
¿cuando se estima que se anuncie los resultados de la fase 3? ¿que fluctuación puede sufrir el precio de la accion en caso de ser postiva/negativa? ¿+-75% como THLD? Gracias! DVAX
Ir a respuesta
23/09/15 11:50
Ha respondido al tema Catenon
Los pasivos los reducen en 1,2M. De efectivo reducen en 0,8 (-1,2 de efectivo +0,4 de Inversiones financieras).
Ir a respuesta
21/08/15 11:28
Ha respondido al tema Opa Abertis
Una duda, una vez se ejecute la OPA el precio abrirá a 15,70 o no necesariamente? Gracias!
Ir a respuesta
11/08/15 09:54
Ha respondido al tema Farmas USA
http://finance.yahoo.com/news/novavax-early-study-indicates-vaccine-201014800.html NVAX
Ir a respuesta
29/07/15 14:16
Ha respondido al tema Farmas USA
NBIX Buenas, ¿Alguno esta o sigue a NBIX? ¿que opinión os merece? Yo entre el lunes a 49,86 con vistas a Diciembre donde tiene 2 Fases 3 y una fase 2. Hoy al cierre resultados, por cierto, quizas me precipite pero queria aprovechar la caida...
Ir a respuesta
24/04/15 21:57
Ha respondido al tema Farmas USA
CPRX Estoy hoy bastante out, pero creo que la estan tirando un 20% porque un competidor ha tenido buenos resultados. ¿no es muy exagerado?
Ir a respuesta
10/04/15 13:27
Ha respondido al tema Farmas USA
$GALE No se si lo habeis comentado pero por si acaso Warning letter: Item 8.01 Other Events As previously reported by Galena Biopharma Inc. (“we,” “us,” “our,” and the “company”) in its Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 5, 2015, following an inspection of our Portland, Oregon facility in November 2014, the U.S. Food and Drug Administration (the “FDA”) issued a Form 483 Notice of Inspectional Observations (the “Form 483 Notice”) noting deficiencies pertaining to post-marketing adverse drug experience reporting and current good manufacturing practices for Abstral and Zuplenz, our only approved products. We responded to the Form 483 Notice in a letter dated December 11, 2014. In conjunction with our response to the FDA, we initiated a number of programs and corrective actions to address the FDA's observations. On April 6, 2015, we received a Warning Letter from the FDA relating to certain of the matters originally identified in the Form 483 Notice. Specifically, the Warning Letter cites deficiencies in our response letter related to the adequacy of our written procedures for the surveillance, receipt, evaluation, and reporting of post-marketing adverse drug experiences from all sources, and the failure to report each adverse drug experience not reported under 21 CFR 314.80(c)(1)(i) at quarterly intervals. The Warning Letter will be posted on the FDA’s website at www.fda.gov and, once posted, will be available for viewing. We have 15 business days to respond to the Warning Letter, and intend to fully respond in a timely manner. We do not expect any interruption in our commercial operations or impact on our 2015 financial guidance as a result of the Warning Letter. However, we cannot give any assurances that the FDA will be satisfied with our response to the Warning Letter or our proposed resolution of the outstanding issues cited by the FDA. Until the issues are corrected, we may be subject to additional regulatory action by the FDA, including the possible withholding or delay of approval of any FDA applications, seizures of our products, and injunctive and civil monetary penalties. Any such actions could disrupt our ongoing business and operations and potentially have a material, adverse impact on our financial condition and operating results. This Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated impact of the FDA’s Warning Letter on our company. We caution that these forward-looking statements are subject to risks, uncertainties and assumptions, many of which are beyond our control that may cause actual results to differ materially from those indicated in the forward-looking statements, for a number of reasons, including without limitation, additional actions by or requests from the FDA. Additional information concerning other factors is contained under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed with the SEC, which are incorporated herein by reference. We undertake no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.
Ir a respuesta
27/03/15 14:56
Ha respondido al tema Farmas USA
Ohr Pharmaceutical Inc. (OHRP: Quote) announced results from its Phase II study of OHR-102 combination therapy for the treatment of the wet form of age-related macular degeneration Friday morning. The study failed to meet its primary endpoint. -65% Por si alguno la llevaba...
Ir a respuesta
26/03/15 17:14
Ha respondido al tema Farmas USA
https://es.finance.yahoo.com/noticias/eeuu-temores-burbuja-burs%C3%A1til-biotecnolog%C3%ADa-154334429.html?utm_source=dlvr.it&utm_medium=twitter
Ir a respuesta
Este sitio web usa cookies para analizar la navegación del usuario. Política de cookies.
Cerrar